• Truist Financial sets a new price target of $16 for CorMedix Therapeutics (NASDAQ:CRMD), indicating an 84.95% potential upside.
• CorMedix reports preliminary unaudited net revenue of $127 million for Q4 and $400 million for the full year of 2025.
• The company's adjusted EBITDA for Q4 is expected to be between $77 million and $81 million, showcasing strong operational performance.

CorMedix Therapeutics, trading on the NASDAQ under the symbol CRMD, is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases. As of January 8, 2026, Truist Financial set a price target of $16 for CRMD, a significant increase from its current trading price of $7.44. This target represents an 84.95% potential upside.

The price target was adjusted from a previous target of $20, as reported by TheFly. Despite this reduction, the new target still suggests a strong growth potential for CRMD. The stock has seen a notable decrease of 34.15%, with a current price of $7.36, down $3.82. This fluctuation highlights the volatility in CRMD's market performance.

CorMedix recently announced its preliminary unaudited financial results for the fourth quarter and full year of 2025. The company reported net revenue of approximately $127 million for the fourth quarter and $400 million for the full year. These figures underscore CorMedix's efforts in its core business activities.

The company also expects its adjusted EBITDA for the fourth quarter to be between $77 million and $81 million. This range indicates a strong operational performance. Additionally, CorMedix disclosed unaudited cash and short-term investments of approximately $148 million, reflecting a solid financial position.

CRMD's market capitalization is approximately $579.5 million, with a trading volume of 20.76 million shares. The stock has fluctuated between a low of $7.22 and a high of $9.36 today. Over the past year, CRMD reached a high of $17.43 and a low of $5.60, showcasing its price volatility.